X-Nico

4 unusual facts about Daiichi Sankyo


Daiichi Sankyo

On June 10, 2008, Daiichi Sankyo agreed to take a majority (35%) stake in Indian generic drug maker Ranbaxy, with a deal valued at about $4.6 billion.

•

The company also owns the American biotechnology company Plexxikon, the German biotechnology company U3 and Ranbaxy Laboratories in India.

•

Daiichi Sankyo Europe, GmbH (DSE), the European subsidiary, is headquartered in Munich, Germany.

Ranbaxy Laboratories

In June 2008, Japan's Daiichi Sankyo Company took a majority (50.1%) stake in Ranbaxy, with a deal valued at about US$4.6 billion.



see also